Antihyperalgesic effects of cizolirtine in diabetic rats: Behavioral and biochemical studies

Pain

Volumn 110, Issue 1-2, 2004, Pages 22-32

  Aubel, Bertrand ^a   Kayser, Valérie ^a   Mauborgne, Annie ^a   Farré, Antonio ^b   Hamon, Michel ^a   Bourgoin, Sylvie ^a  

^a INSERM   (France)

^b Laboratorios Dr Esteve SA   (Spain)

Author keywords

5 HT, 5 hydroxytryptamine, serotonin; ACSF, artificial cerebrospinal fluid; ANOVA, analysis of variance; Cizolirtine; Diabetes; Idazoxan; Intrathecal perfusion; Neuropathic pain; Paroxetine; Paw withdrawal and vocalization thresholds

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; ANTINOCICEPTIVE AGENT; CALCITONIN GENE RELATED PEPTIDE; CIZOLIRTINE; HALOTHANE; OPIATE; PAROXETINE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BEHAVIOR; BIOCHEMISTRY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; EXPERIMENTAL TEST; HYPERALGESIA; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NEUROPATHIC PAIN; NONHUMAN; PRESSURE; PRIORITY JOURNAL; RAT; SENSORY NERVE; SYNAPSE;

ANALGESICS, NON-NARCOTIC; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; CALCITONIN GENE-RELATED PEPTIDE; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRINKING; DRUG INTERACTIONS; GLYCEMIC INDEX; HYPERALGESIA; IDAZOXAN; INFUSION PUMPS, IMPLANTABLE; MALE; PAIN MEASUREMENT; PAIN THRESHOLD; PAROXETINE; PYRAZOLES; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; STREPTOZOCIN; TIME FACTORS;

EID: 3242728595     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2004.03.001     Document Type: Article

References (49)

1. Ahlgren S.C., Levine J.D. Mechanical hyperalgesia in streptozotocin- diabetic rats is not sympathetically maintained. Brain Res. 616:1993;171-175
2. Alvarez I., Andreu F., Buxens J., Colombo M., Dordal A., Fort M., Gutiérrez B., Farré A.J. Pharmacology of cizolirtine: a new analgesic agent. Methods Find Exp Clin Pharmacol. 22:2000;211-221
3. Ardid D., Alloui A., Brousse G., Jourdan D., Picard P., Dubray C., Eschalier A. Potentiation of the antinociceptive effect of clomipramine by a 5-HT(1A) antagonist in neuropathic pain in rats. Br J Pharmacol. 132:2001;1118-1126
4. Ballet S., Aubel B., Mauborgne A., Polienor H., Farré A.J., Cesselin F., Hamon M., Bourgoin A.S. The novel analgesic, cizolirtine, inhibits the spinal release of substance P and CGRP in rats. Neuropharmacology. 40:2001;578-589
5. Benbow S.J., Chan A.W., Bowsher D., MacFarlane I.A., Williams G. A prospective study of painful symptoms, small-fibre function and peripheral vascular disease in chronic painful diabetic neuropathy. Diabet Med. 11:1994;17-21
6. Bitar M.S., Bajic K.T., Farook T., Thomas M.I., Pilcher C.W. Spinal cord noradrenergic dynamics in diabetic and hypercortisolaemic states. Brain Res. 830:1999;1-9
7. Bourgoin S., Pohl M., Mauborgne A., Benoliel J.J., Collin E., Hamon M., Cesselin F. Monoaminergic control of the release of calcitonin gene-related peptide- and substance P-like materials from rat spinal cord slices. Neuropharmacology. 32:1993;633-640
8. Clark C.M. Jr, Lee D.A. Prevention and treatment of the complications of diabetes mellitus. N Engl J Med. 332:1995;1210-1217
9. Collin E., Mantelet S., Frechilla D., Pohl M., Bourgoin S., Hamon M., Cesselin F. Increased in vivo release of calcitonin gene-related peptide-like material from the spinal cord in arthritic rats. Pain. 54:1993;203-211
10. Collin E., Frechilla D., Pohl M., Bourgoin S., Mauborgne A., Hamon M., Cesselin F. Differential effects of the novel analgesic S 12813-4, on the spinal release of substance P- and calcitonin gene-related peptide-like materials in the rat. Naunyn Schmiedebergs Arch Pharmacol. 349:1994;387-393
11. Committee for Research and Ethical Issues of the IASP. Ethical standards for investigations of experimental pain in animals. Pain. 16:1983;109-110
12. Courteix C., Eschalier A., Lavarenne J. Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain. Pain. 53:1993;81-88
13. Courteix C., Bardin M., Chantelauze C., Lavarenne J., Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain. 57:1994;153-160
14. Dabire H. Idazoxan: a novel pharmacological tool for the study of alpha 2-adrenoceptors. J Pharmacol. 17:1986;113-118
15. DCCT. Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol. 38:1995;869-880
16. Farré A.J., Frigola J. Cizolirtine citrate. Drugs Future. 27:2002;721-732
17. Fritschy J.M., Grzanna R. Demonstration of two separate descending noradrenergic pathways to the rat spinal cord: evidence for an intragriseal trajectory of locus coeruleus axons in the superficial layers of the dorsal horn. J Comp Neurol. 291:1990;553-582
18. Gomez-Perez F.J., Rull J.A., Dies H., Rodriquez-Rivera J.G., Gonzalez-Barranco J., Lozano-Castaneda O. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy A double-blind cross-over study. Pain. 23:1985;395-400
19. Goodnick P.J. Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. Ann Clin Psychiatry. 13:2001;31-41
20. Greene D.A., De Jesus P.V. Jr, Winegrad A.I. Effects of insulin and dietary myoinositol on impaired peripheral motor nerve conduction velocity in acute streptozotocin diabetes. J Clin Invest. 55:1975;1326-1336
21. Hylden J.L.K., Thomas D.A., Iadarola M.J., Nahin R.L., Dubner R. Spinal opioid analgesic effects are enhanced in a model of unilateral inflammation/hyperalgesia: possible involvement of noradrenergic mechanisms. Eur J Pharmacol. 194:1991;135-143
22. Jourdan D., Alloui A., Eschalier A. Pharmacological validation of an automated method of pain scoring in the formalin test in rats. J Pharmacol Toxicol Methods. 42:1999;163-170
23. Junod A., Lambert A.E., Stauffacher W., Renold A.E. Diabetogenic action of streptozotocin: relationship of dose to metabolic response. J Clin Invest. 48:1969;2129-2139
24. Kayser V., Farre A., Hamon M., Bourgoin S. Effects of the novel analgesic, cizolirtine, in a rat model of neuropathic pain. Pain. 104:2003;169-177
25. Malcangio M., Tomlinson D.R. A pharmacologic analysis of mechanical hyperalgesia in streptozotocin/diabetic rats. Pain. 76:1998;151-157
26. Martinez L., Serafini M.T., Pretel M.J., Garcia-Soret A., Moragon T., Puig S. Absorption, distribution, metabolism and excretion of cizolirtine, a new analgesic compound, in rat and dog. Xenobiotica. 29:1999;859-871
27. Max M.B., Lynch S.A., Muir J., Shoaf S.E., Smoller B., Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med. 326:1992;1250-1256
28. McQuay H., Carroll D., Jadad A.R., Wiffen P., Moore A. Anticonvulsant drugs for management of pain: a systematic review. Br Med J. 311:1995;1047-1052
29. McQuay H.J., Tramer M., Nye B.A., Carroll D., Wiffen P.J., Moore R.A. A systematic review of antidepressants in neuropathic pain. Pain. 68:1996;217-227
30. Owens M.J., Knight D.L., Nemeroff C.B. Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry. 47:2000;842-845
31. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care. 1:1978;168-188
32. Pohl M., Benoliel J.J., Bourgoin S., Lombard M.C., Mauborgne A., Taquet H., Carayon A., Besson J.M., Cesselin F., Hamon M. Regional distribution of calcitonin gene-related peptide-, substance P-, cholecystokinin-, Met5-enkephalin-, and dynorphin A (1-8)-like materials in the spinal cord and dorsal root ganglia of adult rats: effects of dorsal rhizotomy and neonatal capsaicin. J Neurochem. 55:1990;1122-1130
33. Pohl M., Collin E., Bourgoin S., Clot A.M., Hamon M., Cesselin F., Le Bars D. In vivo release of calcitonin gene-related peptide-like material from the cervicotrigeminal area in the rat. Effects of electrical and noxious stimulations of the muzzle. Neuroscience. 50:1992;697-706
34. Proudfit H.K. Pharmacologic evidence for the modulation of nociception by noradrenergic neurons. Progr Brain Res. 77:1988;357-370
35. Rakieten N., Rakieten L., Nadkarni M. Studies on the diabetogenic action of streptozotocin. Cancer Chemother Rep. 1963;29-91
36. Randall L., Selitto J. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther. 61:1957;409-419
37. Rosenberg J.M., Harrell C., Ristic H., Werner R.A., de Rosayro A.M. The effect of gabapentin on neuropathic pain. Clin J Pain. 13:1997;251-255
38. Simon G.S., Dewey W.L. Narcotics and diabetes I. The effects of streptozotocin-induced diabetes on the antinociceptive potency of morphine. J Pharmacol Exp Ther. 218:1981;318-323
39. Sindrup S.H., Gram L.F., Brosen K., Eshoj O., Mogensen E.F. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain. 42:1990;135-144
40. Takano M., Takano Y., Yaksh T.L. Release of calcitonin gene-related peptide (CGRP), substance P (SP), and vasoactive intestinal polypeptide (VIP) from rat spinal cord: modulation by alpha 2 agonists. Peptides. 14:1993;371-378
41. Troger J., Humpel C., Kremser B., Kralinger M., Teuchner B., Kunze C., Philipp W., Kieselbach G. The effect of streptozotocin-induced diabetes mellitus on substance P and calcitonin gene-related peptide expression in the rat trigeminal ganglion. Brain Res. 842:1999;84-91
42. Tuck R.R., Schmelzer J.D., Low P.A. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain. 107:1984;935-950
43. Vinik A.I., Holland M.T., Le Beau J.M., Liuzzi F.J., Stansberry K.B., Colen L.B. Diabetic neuropathies. Diabetes Care. 15:1992;1926-1975
44. Vinik A.I. Diabetic neuropathy: pathogenesis and therapy. Am J Med. 107:1999;17S-26S
45. Wall P.D., Devor M. Sensory afferent impulses originate from dorsal root ganglia as well as from the periphery in normal and nerve injured rats. Pain. 17:1983;321-339
46. Westlund K.N., Bowker R.M., Ziegler M.G., Coulter J.D. Noradrenergic projections to the spinal cord of the rat. Brain Res. 263:1983;15-31
47. Yagihashi S., Kamijo M., Ido Y., Mirrlees D.J. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats. Diabetes. 39:1990;690-696
48. +-evoked release of serotonin and norepinephrine in vivo from the rat and cat spinal cord. Brain Res. 192:1980;133-146
49. 2 adrenergic agonists and analgesics. Novels aspects of pain management: opioids and beyond. 1999;Wiley, New-York